In my first coverage of Coherus Oncology, Inc. (NASDAQ: CHRS ), I expressed measured optimism for the investment thesis in the wake of their sale of their version of pegfilgrastim, which isI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space. ...